Global Erdosteine Market is Segmented By Dosage Form (Capsule, Dry Suspension, Dispersible tablets, Sachets), By Application (Chronic obstructive pulmonary disease (COPD), Acute bronchitis (AB), Chronic bronchitis (CB), Others), By End-User (Hospital Pharmacy, Retail Pharmacies, Online, Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Erdosteine Market Overview
The Global Erdosteine Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Erdosteine is a mucolytic agent used in the treatment of respiratory disorders. The market is driven by the increasing prevalence of respiratory diseases and the demand for effective therapeutic options. In America, the Global Erdosteine Market is witnessing significant growth. Key players in the market include Company J, Company K, Company L, and other prominent players.
Erdotin contains erdosteine, a mucolytic agent that acts on mucus (phlegm) in the respiratory tract or airways. Erdotin is used to treat the symptoms associated with short, severe episodes of chronic bronchitis worsening. It's also employed as an expectorant.
Erdosteine Market Scope and Summary
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Dosage Form, By Application, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights - Download the Sample
Erdosteine Market Dynamics and Trends
The rising pollution due to industrialization is one of the factors driving the market growth.
The rising pollution due to industrialization is expected to drive the global erdosteine market
Chronic bronchitis develops because of repeated irritation and damage to lung and airway tissues. Other possible causes include long-term exposure to air pollution, dust, and environmental fumes. Sulfur dioxide causes inflammation, which aggravates chronic bronchitis and increases the likelihood of infection. Workplace air pollution causes several non-communicable diseases (NCDs), including chronic bronchitis. Every year, it is estimated that 5% of the general population suffers from acute bronchitis, resulting in more than 10 million office visits. Acute bronchitis, like the majority of viral respiratory diseases, is common during flu season.
Erdosteine, a drug approved for the treatment of acute and chronic pulmonary diseases, is an effective treatment for chronic bronchitis or COPD (CB/COPD), though there are significant differences in perception of its usefulness. Erdosteine works by breaking the disulfide bonds of mucus glycoproteins, altering the physical properties of the mucus and increasing mucus clearance. It also acts as an antioxidant by scavenging free radicals. Furthermore, erdosteine has anti-inflammatory activity, as evidenced by a significant reduction in the levels of pro-inflammatory eicosanoids and cytokines in the blood of COPD patients and the release of inflammatory mediators in severe COPD patients due to exercise-induced oxidative stress. Importantly, erdosteine has antibacterial properties by decreasing bacterial adhesiveness. Hence, with increasing pollution levels the incidence of bronchitis is also expected to increase driving the global erdosteine market growth.
Side-effects of erdosteine are expected to hamper the market growth
Erdotin, like all medications, can cause side effects, though not everyone experiences them. For example, headache; cold and difficulty breathing; taste changes, nausea, vomiting, diarrhoea; swelling of the blood vessels beneath the skin and mucosal tissues due to allergic reaction (angioedema); other skin allergic reactions, such as itching and redness of the skin, oedema, and eczema. Stomach pain is common (heartburn).
Erdotin has a minor or negligible effect on one's ability to drive and operate machinery. Erdosteine has been shown in human studies to be well tolerated in the treatment of wet cough and COPD. Mucolytics, such as erdosteine is contraindicated in patients with a history of peptic ulcers. Erdosteine may be less likely to disrupt the gastric mucosal barrier as a prodrug, but it is also contraindicated in patients with active peptic ulcers.
COVID-19 Impact on Erdosteine Market Growth
On April 8th, 2020, Erdosteine, a proprietary molecule developed by Recipharm, is effective in the treatment of COVID-19. The results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available from Recipharm.
The clinical study included 20 COVID-19 patients with severe respiratory failure who were hospitalized in one of Milan's major COVID-19 centres in Lombardy, the Italian region most affected by SARS-CoV-2. The study found that patients who took Erdosteine after being discharged from the hospital experienced significant improvements in health-related quality of life parameters (HRQoL) and dyspnea. This is one of the first studies to report HRQoL data in patients with COVID-19. Hence, COVID-19 showed a positive impact on the market growth.
Erdosteine Market Segment Analysis
On basis of dosage form, capsules held the largest market share in the global erdosteine market
A capsule is a solid dose in which one or more medicines and excipients are enclosed in a hard or soft soluble shell, typically made of gelatin. A capsule is a common form of oral administration dose. The capsule is used to treat chronic obstructive pulmonary disease and other conditions. Erdosteine capsules can also be used for things that aren't listed in this medication guide. Erdosteine is the active ingredient in the Erdosteine capsule. Erdosteine capsule works by increasing mucociliary transport and modulating mucus production and viscosity.
For example, erdosteine capsule 300mg contains 300 mg of erdosteine. The product appears as a capsule with a green cap and a yellow body. Recipharm announced that its proprietary molecule Erdosteine had been officially recognised as one of the commonly used maintenance medications in COPD by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Scientific Committee (Chronic Obstructive Pulmonary Disease). Recipharm's Erdosteine-containing products are now available in over 40 countries worldwide and come in four different dosage forms, including a capsule.
Erdosteine Market Geographical Share
North America region accounted for the largest market share in the global erdosteine market
The factors driving the market in this region is the increasing prevalence of respiratory disease and opting for early treatment.
Approximately, 37 million Americans suffer from chronic lung diseases, such as asthma or COPD, which includes emphysema and chronic bronchitis. In U.S Deaths due to chronic lower respiratory diseases such as asthma, occupational lung disease, and pulmonary hypertension decreased slightly from 5.7 per cent in 2017 to 5.6 per cent in 2019. There was also a decrease in the death rate, which dropped from 40.9 per 100,000 in 2017 to 39.7 in 2018.
In the United States many years ago FDA designated erdosteine, a drug developed by Edmond Pharma, as an orphan drug for treating bronchiectasis. Hence, increasing demand for respiratory disease treatment is expected to drive the market.
Erdosteine Companies and Competitive Landscape
The global erdosteine market is highly competitive with increasing mergers, FDA approvals and product launches by key companies. Some of the key companies in the global erdosteine market are Edmond Pharma S.R.L., Alitair Pharmaceuticals, Manus Aktteva Biopharma LLP, Reine Life Science., Recipharm AB., Sigma-Aldrich Co. LLC, OEP Philippines, Inc and Genome Pharmaceuticals (Pvt.) Ltd.
Recipharm AB
Overview: Recipharm AB is one of the world's five largest pharmaceutical contract development and manufacturing organizations, with manufacturing facilities in Sweden, France, Germany, Italy, Spain, Portugal, India, the United Kingdom, and development sites in Sweden, Israel, and the United States. It is headquartered in Sweden. The company was founded in 1994.
Product Portfolio: The company develops tablets, capsules, mini tablets
modified release, solubility enhancement, semi-solids, injectables, liquids, and inhalation.
Key Development: On 23rd November 2018, Recipharm's proprietary molecule Erdosteine was officially recognized as one of the commonly used maintenance medications in COPD by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Scientific Committee (Chronic Obstructive Pulmonary Disease)
